Boston CE marks Express2 coronary stent:
This article was originally published in Clinica
Executive Summary
Boston Scientific has CE-marked for sale in Europe its Express2 coronary stent system. The product features the company's Bioslide hydrophilic coating, designed to reduce friction, its proprietary Crimp 360 technology, which secures the stent to the balloon, and a laser-bonded, flexible tip with a long, low profile that allows for easier tracking. The stent, which is also expected to provide a platform for Boston's Taxus drug-eluting stent programme, is scheduled for launch in Europe next week. A US launch is expected in September.
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.